What is HC Wainwright’s Forecast for enGene FY2026 Earnings?

enGene Holdings Inc. (NASDAQ:ENGN) – HC Wainwright raised their FY2026 earnings per share (EPS) estimates for enGene in a research report issued to clients and investors on Tuesday, September 8th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($1.89) for the year, up from their previous estimate of ($1.95). HC Wainwright currently has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for enGene’s current full-year earnings is ($1.83) per share. HC Wainwright also issued estimates for enGene’s Q4 2026 earnings at ($0.55) EPS, FY2027 earnings at ($1.98) EPS, FY2028 earnings at ($1.76) EPS and FY2029 earnings at ($0.76) EPS.

enGene (NASDAQ:ENGN) last issued its earnings results on Tuesday, September 8th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04).

Several other equities research analysts have also issued reports on the stock. Morgan Stanley lowered shares of enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective for the company. in a research note on Thursday, June 18th. Citizens Jmp restated a “market perform” rating on shares of enGene in a report on Wednesday. Citigroup reaffirmed a “market perform” rating on shares of enGene in a research report on Wednesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of enGene in a research note on Wednesday, August 12th. Finally, Wall Street Zen raised enGene from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. Four analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, enGene presently has an average rating of “Hold” and an average target price of $11.05.

enGene Stock Down 4.3%

Shares of enGene stock opened at $1.77 on Friday. The firm has a market cap of $118.57 million, a price-to-earnings ratio of -1.57 and a beta of -0.28. The stock has a 50-day simple moving average of $1.83 and a 200-day simple moving average of $3.93. enGene has a 52-week low of $1.40 and a 52-week high of $12.25. The company has a debt-to-equity ratio of 0.11, a current ratio of 10.21 and a quick ratio of 12.57.

Institutional Trading of enGene

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Cresset Asset Management LLC acquired a new position in shares of enGene during the second quarter valued at about $36,000. Raymond James Financial Inc. increased its stake in enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after acquiring an additional 7,932 shares during the period. Paloma Partners Management Co bought a new position in enGene during the second quarter valued at about $38,000. Jump Financial LLC acquired a new position in enGene in the 4th quarter valued at approximately $121,000. Finally, Millennium Management LLC raised its holdings in enGene by 57.3% in the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after acquiring an additional 7,472 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.